Datapoint: Cigna Expands GLP-1 Program to Limit Payer Costs

Cigna’s pharmacy benefit management unit Evernorth is updating its EncircleRx program to include an “industry-first financial guarantee” for employer clients that choose to cover glucagon-like peptide-1 (GLP-1) receptor agonists, the injectable “cardiodiabesity” drugs that have kept the industry buzzing since their inception. “[EncircleRx] offers employers and health plans greater predictability and control of their GLP-1 spend,” Adam Kautzner, president of Express Scripts and Evernorth Care Management, said in a statement. The expanded program will offer employers a cost cap or savings guarantee on GLP-1 spend. Cigna is one of the largest commercial insurers in the U.S., serving 13.8 million members via self-funded contracting arrangements, and an additional 2.2 million lives in employer group risk-based products.

Source: AIS’s Directory of Health Plans

0

0

0 Comments

0

0

• Datapoint